Here's why the Rhythm (ASX:RHY) share price is soaring 8% today

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22. Here's what the company announced to the ASX.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22.

During early morning trade, Rhythm shares are swapping hands for $1.045, up 8.8%.

Rhythm moves ahead with strategic plans

Investors appear to be pleased with the company's progress to commercialise its cancer detection technology, ColoSTAT, driving Rhythm shares higher.

In its announcement, Rhythm highlighted a number of activities that it is moving forward to launch ColoSTAT into global markets.

The first of its listed strategic initiatives is to accelerate United States market entry for ColoSTAT. The company has incorporated a wholly-owned entity to cement its foothold in the country to carry operations out smoothly. The initial pathway stages to obtain market approval from the United States Food and Drug Administration (FDA) has already commenced.

In addition, Rhythm has expanded its platform by setting up an Australian entity to hold its technology within. The company validated initial data that its lead biomarker has a global market opportunity for cancer diagnostics.

Regulatory entry in both Europe (CE Mark) and Australia is advancing ahead of completion in its ColoSTAT Study 7. CE Mark filing is slated for late 2021, and the Australian Therapeutic Goods Administration (TGA) has begun the regulatory approval process.

Lastly, the company is looking at further market entry strategies in Europe, Australia, New Zealand, China, and broader Asia. Further updates in regards to this are expected to be released to the ASX in the coming months.

Notably, the company is targeting its first revenue for late 2022.

Comments from the CEO

Rhythm CEO, Mr. Glenn Gilbert commented:

Following the exceptional ColoSTAT performance results from Study 6 and the LRF algorithm enhancement work, this has given the company confidence to now accelerate the execution of our commercial strategy, focusing on our path to market activities.

ColoSTAT will transform the global mass-market cancer diagnostic market, with exciting and positive impacts at a social and economic level.

About the Rhythm share price

The Rhythm share price has been one of the best performers over the last 12 months, rising more than 1,000%. The company's shares were trading at 6.3 cents in June before accelerating later that year.

It's worth noting that the Rhythm share price is trading just below its all-time high of $1.675, reached in March.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Healthcare Shares

ResMed share price jumps 10% on strong quarterly update

ResMed has impressed the market with its third-quarter update.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Up 74% in 6 months, guess which ASX 200 healthcare stock just hit another all-time high

This company has busily deployed cash over the past six months while growing at a phenomenal pace.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Broker says this ASX biotech stock could almost double in value

Bell Potter is feeling very bullish about this risky stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Share Gainers

If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!

Mesoblast shares have been on a tear this past month. But why?

Read more »

Woman going for a scan reassured by doctor
Healthcare Shares

How AI could boost this ASX 300 healthcare stock

The Firetrail investment management team see AI providing a 'material tailwind' for this stock.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is the ResMed share price diving 5% today?

Weight loss wonder drugs are weighing heavily on this stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Why is the Telix share price jumping 15% to a record high?

This healthcare stock is scaling new heights on Thursday. But why?

Read more »

Stressed thoughtful old female general practitioner doctor physician looking in distance, considering difficult medical problem solution or illness treatment, working on computer in clinic office.
Healthcare Shares

How much do you need to invest in CSL shares for $8,000 in annual dividends?

CSL's dividends are exponentially more valuable for long-term investors.

Read more »